Five years after the release of the Diversity and Inclusion Action Plan, the University is launching Phase II of the plan. Phase II reiterates the DIAP’s central goals while outlining new actions ...
In the Phase 2 Study of TPN-101 in patients with C9orf72-related ALS, TPN-101 showed clinical benefits on key clinical outcome measures, including slow vital capacity and the ALSFRS-R TPN-101 also had ...
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 - ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore ...
BARCELONA, Spain--(BUSINESS WIRE)--Ferrer, a B Corp-certified international pharmaceutical company, has announced the dosing of the first participant in the Phase II clinical trial, PROSPER. The study ...
In the Phase 2 Study of TPN-101 in patients with C9orf72-related ALS, TPN-101 showed clinical benefits on key clinical outcome measures, including slow vital capacity and the ALSFRS-R TPN-101 also had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results